TY - BOOK ID - 4863633 TI - Antibody-Drug Conjugates : The 21st Century Magic Bullets for Cancer AU - Wang, Jeffrey. AU - Shen, Wei-Chiang. AU - Zaro, Jennica L. PY - 2015 SN - 9783319130811 3319130803 9783319130804 3319130811 PB - Cham : Springer International Publishing : Imprint: Springer, DB - UniCat KW - Biomedicine. KW - Pharmaceutical Sciences/Technology. KW - Medicine. KW - Pharmaceutical technology. KW - Médecine KW - Techniques pharmaceutiques KW - Antibody-drug conjugates. KW - Antibody-toxin conjugates. KW - Drugs -- Research. KW - Health & Biological Sciences KW - Pharmacy, Therapeutics, & Pharmacology KW - Conjugates, Antibody-toxin KW - Immunoconjugates KW - Immunoglobulin-toxin conjugates KW - Immunotoxins KW - Toxin-antibody conjugates KW - Toxin-immunoglobulin conjugates KW - Conjugates, Antibody-drug KW - Drug-antibody conjugates KW - Drug immunoconjugates KW - Drug-immunoglobulin conjugates KW - Immunoconjugates, Drug KW - Immunoglobulin-drug conjugates KW - Bioconjugates KW - Immunopharmacology KW - Immunotoxicology KW - Toxins KW - Drugs KW - Dosage forms KW - Pharmaceutical laboratory techniques KW - Pharmaceutical laboratory technology KW - Technology, Pharmaceutical KW - Technology UR - https://www.unicat.be/uniCat?func=search&query=sysid:4863633 AB - This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field. The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy. Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011). Finally, the volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field. ER -